Mirae Asset Global Investments
PSTX

Mirae Asset Global Investments’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Mirae Asset Global Investments’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-114,011
Closed -$383K – 2678
2023
Q4 		$383K Sell
114,011
-145,918
-56% -$376K ﹤0.01% 2093
2023
Q3 		$619K Buy
259,929
+23,960
+10% +$50.2K ﹤0.01% 1782
2023
Q2 		$415K Buy
+235,969
New +$603K ﹤0.01% 2025

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Mirae Asset Global Investments's PSTX Position: Q1 2024 in Review

Mirae Asset Global Investments sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2024, closing a stake of 114,011 shares — an estimated $383K sold.

Mirae Asset Global Investments first reported a position in PSTX in Q2 2023 and held it in 3 quarters. The position peaked at $619K in Q3 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q1 2024.

  • Mirae Asset Global Investments reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 114,011 Poseida Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $383K.
  • Mirae Asset Global Investments first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • Mirae Asset Global Investments's Poseida Therapeutics, Inc. Common Stock position peaked at $619K in Q3 2023.
  • 91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Mirae Asset Global Investments's 13F filing for Q1 2024, filed 1 May 2024.